With the hype around generative AI (GenAI), there is an increasing demand to explore its capabilities across pharma and MedTech companies, as well as contract research organisations.
Drug development industry stakeholders recognise there is no one-size-fits-all approach to the long-standing challenge of patient recruitment and engagement.
Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<
Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh